Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization

Clinical Trial ID NCT00555594

Rank	Title	Journal	Year	PubWeight™‹?›
1	Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.	Cancer Res	1997	7.95
2	In vivo models of angiogenesis.	J Cell Mol Med	2006	1.74
3	Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin).	Br J Ophthalmol	2006	1.48
4	Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization.	Exp Eye Res	2000	1.15
5	Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing.	Acta Ophthalmol Scand	2004	1.13
6	Histocompatibility testing for keratoplasty in high-risk patients.	Ophthalmology	1983	0.98
7	Beneficial effects of histocompatibility in high-risk corneal transplantation.	Am J Ophthalmol	1982	0.84
8	Angiogenesis factors.	Intern Med	2001	0.84
9	[Angiogenesis and lymphangiogenesis in the cornea. Pathogenesis, clinical implications and treatment options].	Ophthalmologe	2003	0.82
10	Antiangiogenesis agents.	Ophthalmol Clin North Am	2002	0.77